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Administration of anti-4-1BB mAb has been found to be a potent adjuvant when combined with other therapeutic 
approaches, e.g. chemotherapy, cytokine therapies, anti-OX40 therapy, and peptide or DC vaccines. However, 
the adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer has not been fully 
evaluated. In this report, effector T cells were generated in  vitro  by anti-CD3/anti-CD28 activation of 
tumor-draining lymph node (TDLN) cells and used in an adoptive immunotherapy model. While T cells or 
anti-4-1BB alone showed no therapeutic efficacy in mice bearing macroscopic 10-day pulmonary metastases, T 
cells plus anti-4-1BB mediated significant tumor regression in an anti-4-1BB dose dependent manner. Mice 
bearing microscopic 3-day lung metastases treated with T cells alone demonstrated tumor regression which was 
significantly enhanced by anti-4-1BB administration. NK cell depletion abrogated the augmented therapeutic 
efficacy rendered by anti-4-1BB. Cell transfer between congenic hosts demonstrated that anti-4-1BB 
administration increased the survival of adoptively transferred TDLN cells. Using STAT4-/- mice, we found that 
modulated IFNγ secretion in wt TDLN cells after anti-CD3/CD28/4-1BB activation in vitro was lost in similarly 
stimulated  STAT4-/- TDLN cells. Additionally, anti-4-1BB administration failed to augment the therapeutic 
efficacy of T cell therapy in STAT4-/- mice. Together, these results indicate that administered anti-4-1BB mAb can 
serve as an effective adjuvant to augment the antitumor reactivity of adoptively transferred T cells by recruiting 
the host NK cells; increasing the persistence of infused effector T cells, and modulating the STAT4 molecular 
signaling pathway.  
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1.  Introduction 
Adoptive transfer of tumor-reactive T cells 
represents an effective immunotherapeutic strategy for 
cancer treatment. To enhance the efficacy of T cell 
therapy, various strategies have been employed as an 
adjunct to cell transfer. These combined therapies 
include cell transfer in concert with the exogenous 
administration of cytokines (i.e., IL-2) [1,2]; local tumor 
therapies (i.e., irradiation) [3] or genetic modulation 
[4]; active immunization (i.e. DC vaccines) [5]; or 
blockade of immunosuppressive mechanisms (i.e. 
B7-H1 blockade) [6].  
4-1BB (CD137)  is an important co-stimulating 
receptor that is expressed by activated NK cells, T cells 
and DCs [7,8]. 4-1BB ligation can be accomplished with 
agonistic mAb to 4-1BB[9,10]. Engagement of 4-1BB on 
T cells using anti-4-1BB mAb provides a third signal to 
lymphoid cells in conjunction with the stimulus via the 
TCR-CD3 complex and CD28. We reported that 4-1BB 
ligation during CD3/CD28 co-activation of 
tumor-draining lymph node (TDLN) cells in vitro 
shifted T cell responsiveness toward a type 1 cytokine 
pattern with markedly elevated IFNγ and GM-CSF 
secretion [11].  Importantly, these TDLN cells were 
more effective in mediating antitumor reactivity in vivo 
than those activated via CD3 and CD28. TDLN cells 
activated through CD3/CD28/4-1BB ligation showed 
significantly decreased T cell apoptosis and necrosis 
compared with T cells activated via  CD3 alone or 
CD3/CD28 together. This latter observation suggested 
that 4-1BB ligation inhibited activation-induced cell 
death in TDLN cells [11]. 4-1BB/4-1BBL interaction has 
been described in the in vitro generation of human 
CD19 specific CD8+ T cells  for adoptive 
immunotherapy clinical trials [12]. More recently, van 
Rijn et al. compared the activation of human T cells via 
CD3 alone or CD28 and/or human 4-1BB and reported 
superior activation via co-stimulation compared to 
CD3 activation alone [13].  
Anti-4-1BB mAb has also been administrated to 
mediate therapeutic effects in vivo. Chen and 
co-workers were the first to report that anti-4-1BB 
mAb can be administered in vivo to mediate antitumor Int. J. Biol. Sci. 2007, 3 
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responses against established weakly immunogenic 
tumors in animal models [14]. In addition to 
mono-therapy, most of the recent studies have 
involved the administration of anti-4-1BB mAb as an 
adjuvant with other therapeutic approaches. For 
example, anti-4-1BB was administrated as a 
component in combined treatment of cancer with 
chemotherapy [15], or with IL-12 therapy [16]. 
Anti-4-1BB was also used in conjunction with different 
monoclonal antibodies against other co-stimulatory 
molecules [17,18]. For example, concomitant 
therapeutic administration of agonist anti-4-1BB and 
anti-OX40 mAbs mediated rejection of established 
tumors and elicited powerful CD8 T cell responses in 
animal models [17]. In addition, it was reported that 
regression of poorly or non-immunogenic tumors 
required active immunization with a peptide vaccine 
plus anti-4-1BB injection [19]. In weakly and poorly 
immunogenic tumor models, we examined the effects 
of stimulating 4-1BB by administering anti-4-1BB mAb 
after tumor lysate-pulsed dendritic cell (TP-DC) 
vaccination. In established pulmonary and 
subcutaneous tumor models, anti-4-1BB synergistically 
enhanced tumor regression after TP-DC vaccination, 
and improved the survival of treated animals [20].  
It is apparent from these reports that anti-4-1BB 
administration can provide potent in vivo 
co-stimulation of cellular immune responses and may 
therefore serve as a useful reagent in cancer 
immunotherapy.  However, the adjuvant effect of 
anti-4-1BB mAb administration in adoptive T cell 
therapy of cancer has not been fully examined to date. 
I n  t h i s  s t u d y ,  w e  d o c u m e n t e d  t h a t  a n t i - 4 - 1 B B  
administration has a significant adjuvant effect in the 
context of adoptive T cell therapy and have examined 
several mechanisms involved with this effect. 
2.  Materials and Methods 
Mice 
  Female C57BL/6 (B6) mice with a CD45.2 
phenotype were purchased from the Harlan 
Laboratories (Indianapolis, IN). Female CD45.1 mice 
on C57BL/6 background were purchased from The 
Jackson Laboratory (Bar Harbor, ME). The STAT4-/- 
knockout (KO) mice on B6 background were provided 
by Dr. Mark Kaplan from Indiana University. All the 
mice were maintained in specific pathogen-free 
conditions and were used for experiments at 8 weeks 
of age or older. Recognized principles of laboratory 
animals care (NIH publication No. 85-23, revised 1985) 
were followed, and the University of Michigan 
Laboratory of Animal Medicine approved all animal 
protocols.  
Murine tumor cells 
MCA 205 murine tumors are 
3-methylcholanthrene-induced weakly immunogenic 
fibro- sarcomas that are syngeneic to B6 mice. Tumors 
were maintained in vivo by serial subcutaneous (s.c.) 
transplantation in B6 mice and were used within the 
eighth transplantation generation. Tumor cell 
suspensions were prepared from solid tumors by 
enzymatic digestion in 50 ml of Hank’s balanced salt 
solution (HBSS) (GIBCO, Grand Island, NY) 
containing 40 mg of collagenase, 4 mg of 
deoxyribonuclease I and 100 units of hyaluronidase 
(Sigma Chemical Co., St. Louis, MO) for 3 hours at 
room temperature. Tumor cells were washed in HBSS 
3 times before s.c. injection in mice to induce TDLN. 
TDLN preparation 
  To induce TDLN, B6 mice or Stat 4 -/- knockout 
mice were inoculated with 1 x 106 tumor cells in 0.1 ml 
of phosphate buffered saline (PBS) s.c. in the lower 
flank. Nine days later, inguinal TDLN were removed 
aseptically. Multiple TDLN were pooled from groups 
of mice. Lymphoid cell suspensions were prepared by 
mechanical dissociation with 25-gauge needles and 
pressed with the blunt end of a 10-mL plastic syringe 
in HBSS. The resultant cell suspension was filtered 
through nylon mesh and washed in HBSS. 
Activation of TDLN cells  
  TDLN cells were activated with 1.0 μg/ml 
anti-CD3 mAb plus 1.0 μg/ml anti-CD28 mAb (BD 
Pharmingen, San Diego, CA) immobilized in 24-well 
plates (4 x 106 cells/2ml/well) or 6-well plates (20 x 106 
cells/10ml/well) at 37oC with 5% CO2 for two days. 
For antibody immobilization, each well of a 24-well 
cell culture plate (Costar, Cambridge, MA) was coated 
with 1 ml of anti-CD3 plus anti-CD28 at 4°C overnight 
or at room temperature for 5 to 6 hours. After antibody 
activation, the cells were harvested and counted. The 
cells were then expanded in complete media (CM) [11] 
containing human recombinant IL-2 (Chiron 
Therapeutics, Emeryville, CA) starting at a 
concentration of 3 x 10
5 cells per ml in 6-well culture 
plate (Costar) for three days. The concentration of IL-2 
was 80 international units (IU)/ml. At the end of the 
cell expansion, cells were harvested and counted to 
determine the fold of expansion and were used for 
adoptive transfer.  
 In some experiments, w ild type (wt) or Stat4 -/- 
TDLN cells were activated with anti-CD3 and 
anti-CD28 (1.0 μg/ml each) plus soluble anti-4-1BB 
mAb (rat IgG1, BD Pharmingen) at 2.5 μg/ml. 
Secondary cross-linking antibody (anti-rat IgG1) was 
used (10 μg/ml) together with anti-4-1BB mAb. 
Supernatant was then collected at the end of cell 
activation for cytokine analyses.  
Treatment of established pulmonary metastases  
Pulmonary metastases were established via tail 
vein injection of viable MCA 205 cells (2 x 105 ) in B6 or 
Stat4-/- mice. Three or ten day tumor-bearing mice 
were infused intravenously (i.v.) with TDLN cells 
activated with anti-CD3/anti-CD28 and expanded in 
IL-2. Commencing on the day of the cell transfer (day 
0), intraperitoneal (i.p.) injections of IL-2 (40,000IU) 
were administered in 0.5 ml of PBS and continued 
twice daily for eight doses. To some groups, anti-4-1BB 
mAb (25 or 100 μg/ mouse) was administrated i.p. in 
0.5 ml of PBS on day 0 and day 3. Agonistic anti-4-1BB Int. J. Biol. Sci. 2007, 3 
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mAb (1D8) was kindly provided by Bristol-Myers 
Squibb Company, Pharmaceutical Research Institute 
(Princeton, NJ). At least five mice were used in each 
experimental group. Approximately 17 days (for 3-day 
lung metastases) or 24 days (for 10-day lung 
metastases) after tumor injection, all mice were 
sacrificed, and lungs were harvested for enumeration 
of pulmonary metastatic nodules. The metastases 
appeared as discrete white nodules on the black 
surface of lungs insufflated with a 15% solution of 
India ink.  
In vivo NK cell depletion 
Anti-NK1.1 hybridoma cells (HB191; American 
Type Culture Collection, Manassas, VA) were used to 
produce the PK136 mAb for NK cell depletion. MAb 
was purified from ascites fluid by ImmunoPure 
Immobilized Protein A/G gel (Pierce, Biotechnology, 
Rockford, IL). The optimal procedure for in vivo NK 
depletion was 400 μg PK136 mAb /mouse i.p. one day 
before T cell transfer followed by a second injection 5 
days later. This was determined in preliminary 
functional assays of NK activity and flow cytometry 
(data not shown).  
Preparation of splenocytes 
Spleens were harvested from control (PBS) or 
anti-4-1BB mAb treated mice. The weight was scaled 
and spleens were dissociated into cell suspension 
individually. The cell suspension was treated with 
lysis buffer (0.83% NH4Cl, 0.1% KHCO3, and 0.004% 
EDTA) for 1 minute to deplete erythrocytes. The 
resultant cells were washed twice, resuspended, and 
the total number of splenocytes was counted. 3x10^6 
cells of each sample were used for the FACS analysis. 
Preparation of blood samples 
Blood samples were collected into EDTA-coated 
tube. 70 μl of blood samples was treated with blood 
cell lysis buffer (0.8% NH4Cl, 0.08% NaHCO3, and 
0.004% EDTA) for 1 minute to deplete erythrocytes. 
The resultant cells were then washed three times, 
counted and used for FACS staining.  
Fluorescence activated cell sorter (FACS) analysis  
To evaluate the effect of anti-4-1BB on the in vivo 
persistence of adoptively transferred TDLN cells, 
congeneic mice were used as donors for TDLN cells. 
TDLN cells were induced in CD45.1 B6 mice, activated 
with anti-CD3/anti-CD28 and expanded in IL-2. These 
cells were then infused intravenously into naive 
C D 4 5 . 2  B 6  m i c e  o n  d a y  0 .  A n t i - 4 - 1 B B  ( 1 0 0  μg) was 
administrated i.p. on day 0 and day 3. Each group (PBS 
or anti-4-1BB treated) consisted of 15 mice that 
received 5×106  – 7.5×106 cells per mouse. Blood 
samples were collected on days 1, 4, and 9 after 
adoptive transfer. Spleens were also harvested on 
these days. Five mice from each group were used at 
each time point. After lysis of RBCs, Fc receptors were 
blocked with anti-CD16/CD32 mAb, and cells were 
stained using R-PE–conjugated anti-CD45.1 (A20) and 
PE-Cy5 conjugated anti-CD3 mAbs (both from BD 
Pharmingen). Isotype-matched control mAbs were 
used as recommended by the manufacturer. Cells were 
fixed with 2% paraformaldehyde, and analyzed within 
24 hours in a FACScan flow cytometer (Becton Dickson 
& Co., Mountain View, CA). Immediately before 
analysis, a known quantity of 50 µl of polystyrene 
microbeads (Bangs Laboratories, Fishers, IN) was 
added to each sample. For each sample, 1.2×106 events 
were acquired and analyzed. FL2 versus FL3 dot plots 
were gated on forward and side scatter properties of 
the adoptively transferred cells, and the number of 
CD45.1/CD3 double positive cells were recorded. The 
absolute number of cells of interest in each blood 
sample was calculated using the following formula: 
(number of cells of interest analyzed in sample) × 
(number of beads added to sample) / (number of 
beads analyzed in sample). Data acquired from 
samples stained with isotype control Abs were 
subtracted from the data obtained from corresponding 
samples stained with the Abs of interest. The number 
of CD45.1/CD3 positive cells in spleens was calculated 
as (number of cells of interest in sample) x (total 
number of splenocytes)/ (3x10^6).  
Assessment of cytokine release 
  TDLN cells were activated with 
anti-CD3/anti-CD28 in the presence or absence of 
soluble anti-4-1BB mAb plus secondary cross-linking 
antibody as described above. The supernatant was 
then collected and analyzed for IFNγ secretion using 
commercially available enzyme linked 
immunofluorescence assay (ELISA) kits (BD 
Pharmingen). Briefly, 96 well plates (Costar) were 
coated with capture anti-mouse IFNγ (at 1:250 
dilution) at 4°C overnight. Plates were then washed 
three times with PBS-Tween 20 (0.05%)(PBST) before 
being blocked with PBS-FBS (10% v/w) for 1 h at 37°C. 
Plates were washed again with PBST and incubated 
with serially diluted standard (recombinant mouse 
IFNγ, starting at 2000 pg/ml) and supernatant samples 
for 2 h at room temperature. Plates were washed five 
times before IFNγ levels  in the samples were 
determined by incubation with biotin anti-mouse IFNγ 
(at 1:250 dilution) plus Streptavidin-HRP (horseradish 
peroxidase) for 1h at room temperature. Plates were 
washed seven more times before the substrate was 
added. After terminating the enzymatic reaction with 
2N H2SO4, ODs were measured on a microplate reader 
at 490nm. 
Statistical analysis 
  In adoptive transfer model, the significance of 
differences in numbers of metastatic nodules between 
experimental groups was determined using one-way 
analysis of variance followed by a Newman-Keuls post 
hoc test. Two-sided p values of <0.05 were considered 
statistically significant between two groups. Student 
t-test was used to analyze cytokine release data. Int. J. Biol. Sci. 2007, 3 
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3.  Results 
1. Administered anti-4-1BB mAb can serve as an 
effective adjuvant to augment the antitumor 
reactivity of adoptively transferred TDLN cells 
The  in vivo a d j u v a n t  e f f e c t  o f  a n t i - 4 - 1 B B  
monoclonal antibody was examined in an adoptive 
immunotherapy model. We evaluated the antitumor 
activity of adoptively transferred TDLN cells and/or 
anti-4-1BB administration in animals with advanced 
(10-day) MCA 205 pulmonary metastases. Effector T 
cells were TDLN cells activated with 
anti-CD3/anti-CD28 followed by expansion in IL-2 as 
described in the Materials and Methods. Mice with 
10-day established MCA 205 pulmonary metastases 
were treated by the adoptive transfer of TDLN cells 
with or without anti-4-1BB mAb administration. 
Approximately two weeks after treatment, all mice 
were euthanized for enumeration of pulmonary 
metastatic nodules. As shown in Figure 1, mice treated 
with T cells alone or anti-4-1BB alone showed no 
therapeutic efficacy. However, the combination of T 
cell transfer plus anti-4-1BB administration resulted in 
the reduction of metastatic tumor in an anti-4-1BB 
dose-dependent fashion. At a higher dose (100μg) of 
anti-4-1BB used in these experiments, T cell therapy 
combined with anti-4-1BB administration resulted in 
significant tumor regression compared with all other 
groups (p<0.05). There experiments have therefore 
demonstrated a synergism between T cell adoptive 
transfer and anti-4-1BB injection in generating an 
immune response within the host to reject advanced 
tumor burdens. 
 
Figure 1. Anti-4-1BB mAb administration augments the 
efficacy of adoptive T cell therapy in the treatment of 10-day 
established MCA 205 pulmonary metastases. B6 mice were 
inoculated i.v. with 2 x 10
5 MCA 205 tumor cells to induce 
pulmonary metastases. Mice with 10-day established pulmonary 
metastases were treated either by the adoptive transfer of 
anti-CD3/anti-CD28-activated MCA 205 TDLN cells alone, or 
with anti-4-1BB alone at 25 μg or 100 μg i.p. on days 0 and 3 
following T cell adoptive transfer on day 0, or with T cells plus 
anti-4-1BB administration. Commencing on the day of the cell 
transfer (day 0), intraperitoneal (i.p.) injections of IL-2 
(40,000IU) were administered in 0.5 ml of PBS and continued 
twice daily for eight doses. *p<0.05 compared with any other 
groups. Data are representative of two independent experiments. 
 
2. Anti-4-1BB administration-enhanced therapeutic 
efficacy is partially mediated by host NK cells.   
We identified NK cells as well as CD4+ and CD8+ 
T cells as the effectors involved in the tumor rejection 
response associated with tumor lysate-pulsed 
dendritic cell vaccination plus anti-4-1BB therapy in 
one of our previous reports [20]. To examine the role 
played by the host NK cells during adoptive T cell 
transfer plus anti-4-1BB-mediated antitumor reactivity, 
w e  d e p l e t e d  N K  c e l l s  d u r i n g  t h e  c o u r s e  o f  t h e  
combined therapy. In these antibody depletion 
experiments, mice were inoculated with MCA 205 
tumor cells i.v. on day -3 and received the first 
depleting anti-NK1.1 mAb (400 μg, i.p.) on day -1. On 
day 0, anti-CD3/anti-CD28-activated MCA 205 TDLN 
cells were transferred accompanied by IL-2 
administration as described in the Materials and 
Methods. Anti-4-1BB (100μg, i.p) was administrated on 
day 0 and day 3. A second dose of NK depleting mAb 
was administered on day 5. The adequacy of depletion 
was documented by flow cytometry of splenocytes 
retrieved from the treated mice (data not shown). 
Lungs were harvested on day 15 and pulmonary 
metastases were enumerated. As depicted in Figure 2, 
the antitumor efficacy of T cell therapy with IL-2 
injection was significantly enhanced by the 
administration of anti-4-1BB mAb. However, this 
enhancement was significantly abrogated by the 
depletion of NK cells. These data suggested that NK 
cells are essential in the antitumor activity of T cell 
transfer plus anti-4-1BB administration. 
 
Figure 2. Anti-4-1BB mAb-enhanced therapeutic efficacy is 
partially mediated by host NK cells. Treatment of 3-day 
established MCA 205 pulmonary metastases was performed as 
in Figure 1, but neutralizing anti-NK1.1 mAb was used to 
deplete NK cells. MCA 205 tumor cells were injection on day 
-3 to establish pulmonary metastasis. Anti-NK1.1 (400 
μg/mouse) was injected i.p. to deplete host NK cell on day -1 
and day 5. Activated and expanded TDLN cells (2x10^6) were 
transferred on day 0 with IL-2 administration. Anti-4-1BB 
mAb (100 μg) was administrated i.p. on day 0 and day 3. 
Lungs were harvested two weeks later for enumeration of 
pulmonary metastatic nodules. *p < 0.05 versus all other groups. 
Data are representative of two independently performed 
experiments. 
 Int. J. Biol. Sci. 2007, 3 
 
459
3. Anit-4-1BB administration increases the survival 
of adoptively transferred TDLN cells 
We proceeded to evaluate the survival of 
adoptively transferred TDLN cells by using the 
CD45.1/B6 congeneic mouse as a donor strain. TDLN 
cells were induced in these mice and activated with 
anti-CD3 plus anti-CD28 followed by IL-2 expansion 
as in previously experiments. Activated and expanded 
TDLN cells were then transferred (i.v) into CD45.2/B6 
mice. Anti-4-1BB (100 μg) was administrated (i.p.) on 
the same day as cell transfer and 3 days later. Serial 
splenocyte and blood samples were obtained at 
various time points after cell infusion, and the absolute 
numbers of CD45.1+/CD3+ cells were assessed in the 
spleen and in the blood respectively. The persistence of 
the transferred TDLN cells in the spleen (mean 
number of 5 mice each group) is illustrated in Figure 
3A. In two of two experiments performed, at an early 
time point (day 1), there was minimal difference 
regarding the persistence of the infused CD45.1+/CD3+ 
cells between the groups with or without anti-4-1BB 
administration. However, 4 days later, we found 
significantly (p<0.05) more donor cells in the group of 
mice which had received anti-4-1BB. This difference 
disappeared in the spleen at a later time point (day 9). 
In blood (Figure 3B), the infused CD45.1+/CD3+ donor 
cells persisted in higher numbers in the hosts 
administrated with anti-4-1BB than in those without 
anti-4-1BB administration. These differences reached 
statistical significance (P<0.05) at the late time point 
(day 9) evaluated in this study after adoptive transfer. 
These experiments indicate that anti-4-1BB 
administration increased the survival of adoptively 
transferred TDLN cells. 
 
 
 
  
 
Figure 3. Anti-4-1BB administration enhances the survival of adoptively transferred TDLN cells. CD45.2 mice received 
intravenous adoptive transfer of activated and expanded CD45.1 TDLN cells on day 0. Anti-4-1BB (100μg/mouse) was 
administrated i.p on day 0 and day 3. Spleens were harvested and blood samples were collected on days 1, 4, and 9 after cell infusion. 
The absolute number of donor CD45.1
+CD3
+ cells was determined using fluorochrome-conjugated mAb staining and flow 
cytometry analysis as described in Materials and Methods. A, Data are reported as the mean number of CD45.1
+CD3
+ cells of 5 
mice/group in the spleen. Two independently performed experiments are shown. B, Mean number of CD45.1
+CD3
+ cells detected 
per 70 microliter of blood per mouse. There were 5 mice each group.  
 
4. Anti-4-1BB-elicited therapeutic efficacy involves 
STAT4 molecular signaling pathway 
We previously examined the effects of anti-4-1BB 
on anti-CD3/anti-CD28 activated TDLN cells in vitro 
[11]. In that study, addition of anti-4-1BB polarized 
anti-CD3/anti-CD28 activated TDLN cells towards a 
type 1 profile and augmented their therapeutic efficacy 
in the adoptive immunotherapy of established tumor. 
We subsequently reported that anti-4-1BB mAb Int. J. Biol. Sci. 2007, 3 
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administration augmented the antitumor efficacy of 
DC-based vaccines, and the enhanced antitumor 
efficacy was once again due to the polarization effect of 
administered anti-4-1BB in shifting tumor-reactive T 
cells toward the type 1 phenotype [20]. STAT4 is 
well-known to be an important transcription factor for 
the development of Th1 cells [21]. To identify the 
molecular mechanisms which may be involved in the 
adjuvant effect of anti-4-1BB, we evaluated the role of 
STAT4 signaling pathway in the following 
experiments.  
We used STAT4-/- knockout mice to compare the 
immune response of anti-4-1BB-cultured STAT4-/- 
TDLN cells with that of similarly treated wt TDLN 
cells. As shown in Figure 4, in two of the two 
independently performed experiments, ligation of 
4-1BB during anti-CD3/anti-CD28 activation 
significantly enhanced the IFNγ production by 
anti-CD3/anti-CD28-activated wt TDLN cells 
(p<0.001). However, STAT4-/- TDLN cells activated by 
anti-CD3/anti-CD28 secreted comparable (p>0.05) 
amounts of IFNγ either with or without the use of 
anti-4-1BB. These in vitro data suggested that the 
STAT4 signaling pathway may be involved in 
4-1BB-induced immune function of TDLN cells.  
As a corollary, we examined involvement of the 
STAT4 signaling pathway when anti-4-1BB was used 
in vivo. Anti-CD3/anti-CD28-activated and 
IL-2-cultured STAT4-/- TDLN cells were adoptively 
transferred into tumor-bearing STAT4-/- mice, 
followed by IL-2 administration. A separate group of 
mice also received anti-4-1BB administration (Figure 
5). While T cells with IL-2 administration mediated 
tumor regression to certain extent compared with T 
cells alone, anti-4-1BB administration failed to enhance 
the therapeutic effect mediated by T cells plus IL-2 in 
the STAT4-/- hosts.   
These  in vitro and in vivo results support the 
conclusion that the STAT4 signaling pathway is 
involved in anti-4-1BB-evoked antitumor immunity 
during adoptive T cell therapy of cancer.  
 
Figure 4: Lack of modulated IFNγ secretion in STAT4
-/- TDLN 
cells post CD3/CD28/4-1BB activation in vitro. TDLN cells 
from wt or STAT4
-/- mice were activated with 
anti-CD3/anti-CD28 with or without anti-4-1BB followed by 
culture in IL-2. Supernatants at the end of cell culture were 
collected to examine the IFNγ  secretion using ELISA. Two 
independently performed experiments are shown.  
 
 
 
Figure 5:  Anti-4-1BB administration fails to augment the 
therapeutic efficacy of T cell therapy in STAT4
-/- mice. MCA 
205 TDLN cells were induced in STAT4
-/- mice and were 
activated with anti-CD3/anti-CD28 followed by IL-2 expansion 
to generate effector T cells for adoptive therapy.  Three-day 
MCA205 pulmonary metastases were established in the 
STAT4
-/- mice as in Figure 3. Activated and expanded STAT4
-/- 
TDLN cells (2x10^6) were adoptively transferred into tumor 
bearing STAT4
-/- mice followed by IL-2 injection (4x10^4 IU 
twice daily for 4 days) with or without anti-4-1BB 
administration (100μg on day 0 and day 3 relevant to T cell 
transfer on day 0). Fifteen to 17 days after tumor injection, all 
mice were euthanized for enumeration of pulmonary metastasis 
nodules. Data are representative of two independently 
performed experiments. 
4.  Discussion 
In this study, we evaluated the adjuvant effect of 
administrated anti-4-1BB monoclonal antibody in 
adoptive T cell therapy of cancer. Anti-4-1BB 
administration augmented the therapeutic efficacy of 
adoptively transferred TDLN cells in mediating the 
regression of established metastatic tumor in a dose 
dependent fashion and prolonged the survival of the 
treated mice. Mechanistically, the salutary effects of 
anti-4-1BB when administered in conjunction with T 
cell transfer are mediated via several pathways. These 
include the modulation of host NK cells, increased 
survival/persistence of the infused T cells, and the 
involvement of STAT4 signaling pathway.   
Several reports examining anti-4-1BB alone as an 
antitumor therapy have found CD8+ cells to be critical 
[14,22]. The major role of CD8+ cells as effectors may 
relate to the relatively greater expression of 4-1BB on 
CD8+ cells compared to CD4+ cells after T cell receptor 
engagement [23]. Another host component that may 
also be playing a significant role in cancer therapy are 
NK cells [24,25]. Indeed, we previously found that the 
in vivo antitumor reactivity of anti-4-1BB mAb plus DC 
vaccination was mediated by CD8+ cells, CD4+ cells, 
and NK cells [20]. Wilcox et al. also reported that 
4-1BB-stimulated NK cells promote the expansion of 
CD8+ cytolytic T cells in vitro, thus providing another 
form of help [26]. In our current study, depletion of 
NK cells in the receipt mice significantly abrogated Int. J. Biol. Sci. 2007, 3 
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anti-4-1BB augmented therapeutic efficacy of 
adoptively transferred TDLN cells, hence 
demonstrating an important role played by host NK 
cells in the combined therapy with T cell transfer plus 
anti-4-1BB. Yang and colleagues reported that wild 
type cells from the K1735 melanoma (K1735-WT) were 
rejected following vaccination with cells K1735-1D8 
transfected  to express scFv from the anti-4-1BB 
monoclonal antibody 1D8,  and that NK cells were 
needed  for this rejection. Furthermore, tumors 
harvested after mice had been transplanted with 
K1735-1D8 cells or  a mixture of K1735-1D8 and 
K1735-WT cells contained more NK cells. They also 
found that the percentage of NK cells was higher in 
B16-1D8 melanomas expressing anti-4-1BB scFv than 
in the B16-WT tumors [27]. These studies revealed a 
clear association of tumor infiltrating NK cells and 
tumor rejection. While NK cells were found to interact 
with the adaptive immune system in the type 1 
polarization process in our previously described 
anti-4-1BB administration/DC vaccine setting [20], the 
mechanisms involved in the present anti-4-1BB 
administration/T cell transfer study remain to be 
further elucidated.   
 Utilization of congenic animals allowed us to 
track adoptively transferred TDLN cells using a mAb 
to CD45.1. We observed that administration of 
anti-4-1BB mAb following T cell transfer resulted in 
significantly increased in vivo persistence of the 
infused donor cells. Several groups have previously 
reported that anti-4-1BB can promote survival of CD8+ 
T cells [28-30]. Takahashi et al [18] reported that the 
combined  in vivo administration of anti-4-1BB mAb 
with staphylococcal enterotoxin A in mice resulted in 
an increased persistence of staphylococcal enterotoxin 
A-reactive CD8+ T cells in the treated hosts compared 
to a deletion of these antigen-reactive T cells if 
anti-4-1BB was not given. Kwon and coworkers have 
previously reported that both CD4+ and CD8+ T cells 
activated with anti-CD3 mAb increased survival in 
vitro when 4-1BB was ligated [31,32].  Our results 
extend these observations by demonstrating that the 
administrated anti-4-1BB mAb was able to increase the 
persistence of adoptively transferred TDLN cells in 
spleen and in peripheral blood. The lymphodepleted 
host environment appears to promote the persistence 
of transferred effector T cells resulting in improved 
therapeutic effects [33]. These results provide evidence 
to support the development of novel strategies to 
extend the survival and persistence of adoptively 
transferred T cells in the tumor-bearing host in order to 
increase the therapeutic effectiveness. In one of our 
recent reports, we found that ligation of 4-1BB during 
anti-CD3/anti-CD28 activation of TDLN cells in vitro 
significantly increased the cell yield by preventing 
activation-induced cell death via a mechanism 
involving the up-regulation of Bcl-2 and Bcl-xL 
molecules [34]. Further studies to evaluate if 
anti-4-1BB administration enhances the survival of 
effector cells in vivo by modulating anti-apoptotic Bcl 
gene family molecules, as well as the studies to 
demonstrate anti-4-1BB administration-induced cell 
proliferation and trafficking in vivo would provide 
further evidence for anti-4-1BB-induced antitumor 
activity in adoptive immunotherapy of cancer. In 
addition, the survival of tumor Ag specific T cells 
could be investigated by using transgenic animal 
models, such as the OT-1/OVA model, as we have 
successfully used in one of our previous studies [20].  
We described in this study that co-stimulation of 
4-1BB with CD3 and CD28 significantly augmented 
IFNγ production by the activated wt TDLN cells. We 
have previously reported that T cells that manifest 
type 1 cytokine release in response to tumor antigen 
are requisite for mediating tumor regression in an 
adoptive transfer model, and that type 2 responsive T 
cells are immunosuppressive [35]. We have also 
reported that the type 1 (IFN-γ): type 2 (IL-10) cytokine 
ratio of adoptively transferred VPLN cells correlated 
with their ability to mediate tumor regression in 
patients with advanced renal cell cancers [1]. The Th1 
response is mediated through STAT4 [21,36], whereas 
Th2 differentiation is STAT6-dependent [37,38]. In this 
study, the role of STAT4 in this phenomenon was 
revealed by using the STAT4-/-  mice.  In vitro, the 
modulated IFNγ secretion by 
CD3/CD28/4-1BB-activated wt TDLN cells was lost in 
STAT4-/- TDLN cells. In adoptive transfer experiments, 
anti-4-1BB administration failed to augment the 
therapeutic efficacy of T cell therapy in STAT4-/- mice 
a s  t h e y  d i d  i n  w t  h o s t s .  O u r  in vitro and in vivo 
experiments have thus provided direct evidence and 
support the conclusion that the STAT4 signaling 
pathway is involved in anti-4-1BB elicited antitumor 
immunity in adoptive T cell therapy of cancer. 
Nevertheless, in our adoptive transfers conducted in 
this regards, both the donor and the host were 
STAT4-deficient. Since anti-4-1BB was administered 
systemically right after T cells were infused, this 
antibody could impact both on the infused T cells and 
on the host T cells. To further understand which cells 
require STAT4 in order for anti-4-1BB to mediate its 
effects, effector T cells can be generated from wt 
donors and then transferred into tumor-bearing 
STAT4-/- hosts, and visa versa, plus anti-4-1BB 
administration. These criss-cross adoptive transfers 
should allow us to understand if the administrated 
anti-4-1BB has a direct effect on the transferred cells or 
on the host.  
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